SLN · NASDAQ · STOCK
Silence Therapeutics (SLN) Stock Analysis
$9.86
52W $4.19 – $17.58
43/100
$465.73M
-2.6
1.42
Is SLN Bullish or Bearish?
Mixed.
Innellis AI committee rates Silence Therapeutics plc (SLN) Watch with a composite score of 43/100
, based on 6 analysts with 67% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +16.53 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -3.47 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case. Growth Analyst remains cautious — revenue declining -98.6% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
Insufficient data for bull case.
Bear Case
- ROE of only -103.3% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 2.02 adds balance-sheet risk to the value case — Value
- Revenue declining -98.6% YoY -- this is not a growth story right now — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- RSI at 26 is in oversold territory (could mean either capitulation or a bounce setup) — Technical
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
43/100
Agreement
67%
Analysts
6
Conviction
Contested
Sector Rank
Top 100%
of 192 Healthcare peers
Value Analyst
bearish
40
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− ROE of only -103.3% -- cheap may mean cheap for a reason
Growth Analyst
bearish
25
/ 100 · Moderate confidence
Growth story is weak, decelerating, or inconsistent
− Revenue declining -98.6% YoY -- this is not a growth story right now
Technical Analyst
bearish
38
/ 100 · High confidence
Price action is deteriorating -- trend and/or momentum are working against this name
− RSI at 26 is in oversold territory (could mean either capitulation or a bounce setup)
Risk Analyst
bearish
32
/ 100 · Moderate confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 2.02) amplifies downside in a stress scenario
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
60
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
− No news coverage in the last 14 days -- limited independent confirmation either way
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 43.5 to 43.5.
- New bearish signals: 2 appeared.
- Bearish pressure eased: 2 signal(s) disappeared.
Analyst-level changes:
- Risk Analyst: +1 bearish signal(s).
- Technical Analyst: +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
25.7
Oversold
MACD Histogram
-0.162
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Mixed
Support
$5.74
Resistance
$17.51
Bollinger %B
0.18
Inside Bands
Price vs Moving Averages
EMA 9
$10.26
Below
EMA 21
$11.12
Below
EMA 50
$11.57
Below
EMA 200
$9.21
Above
Fundamental Analysis
Valuation
87
Growth
50
Profitability
19
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-2.6×
P/B Ratio
4.04×
PEG Ratio
-0.19
Dividend Yield
0.00%
52W High
$17.58
52W Low
$4.19
Quality & Growth
ROE
-14222.5%
ROA
-6741.5%
Gross Margin
5100.1%
Operating Margin
—
Revenue Growth YoY
—
Debt / Equity
0.00
AI Fundamental Assessment
P/E ratio of -2.6 (inexpensive relative to a 15-40x range); Price-to-book of 4.0x; PEG ratio of -0.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -142.2%; Return on assets of -67.4%; Net margin of -9759.2%; Gross margin of 51.0%; Current ratio of 7.42 (healthy short-term liquidity); Debt-to-equity of 0.00; Free cash flow per share is negative (-2.69); EPS growth decelerating (+158.0% -> -222.0% QoQ); Average YoY EPS growth of 158.0%
Get the Full SLN Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →